Abionyx   Report issue

For profit Phase 3
Founded: Labege France (2005)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2011
NCT01201837
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Cerenis Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

cer-001 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Atherosclerosis (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipoproteinemia Type II (Phase 2)

Hypoalphalipoproteinemias (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1